A majority of adult patients with β-thalassemia who require regular red blood cell (RBC) transfusions experienced clinically meaningful and durable transfusion burden reduction associated with luspatercept (Reblozyl) in the phase III BELIEVE trial.
Lynne Lederman, PhD
Advertisement
Articles by Lynne Lederman, PhD
Advertisement
Latest Updated Articles
Reducing Transfusion Burden in Patients With Beta-ThalassemiaPublished: December 11th 2019 | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
T-DXd Plus Pertuzumab Sustains PFS Benefit Across HER2+ BC Subgroups
2
Sacituzumab Govitecan/Pembro Maintains QOL, Physical Functioning in mTNBC
3
Patient Satisfaction, Comfort Level, and Operational Benefits of SubQ Immune Checkpoint Inhibitors
4
Operationalizing SubQ Immune Checkpoint Inhibitors in Clinical Practice
5
